Schwinger model on an interval: Analytic results and DMRG
Physical Review D · 17.03.2023 · 107 (5)
DOI: 10.1103/physrevd.107.054506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physical Review D, online erschienen am 17.03.2023. Verfasst von Takuya Okuda. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Japan Society for the Promotion of Science, Extreme Universe.
Abstract (Originalsprache)
Quantum electrodynamics in $1+1$ dimensions (Schwinger model) on an interval admits lattice discretization with a finite-dimensional Hilbert space, and is often used as a testbed for quantum and tensor network simulations. In this work we clarify the precise mapping between the boundary conditions in the continuum and lattice theories. In particular we show that the conventional Gauss law constraint commonly used in simulations induces a strong boundary effect on the charge density, reflecting the appearance of fractionalized charges. Further, we obtain by bosonization a number of exact analytic results for local observables in the massless Schwinger model. We compare these analytic results with the simulation results obtained by the density matrix renormalization group (DMRG) method and find excellent agreements.
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science
- Extreme Universe
Zitieren
APA
Okuda, T. (2023). Schwinger model on an interval: Analytic results and DMRG. Physical Review D, 107(5). https://doi.org/10.1103/physrevd.107.054506
Vancouver
Okuda T. Schwinger model on an interval: Analytic results and DMRG. Physical Review D. 2023;107(5). doi:10.1103/physrevd.107.054506
BibTeX
@article{Okuda2023,
author = {Okuda, Takuya},
title = {Schwinger model on an interval: Analytic results and DMRG},
journal = {Physical Review D},
year = {2023},
volume = {107},
number = {5},
doi = {10.1103/physrevd.107.054506}
}
EUVIMED